FDA Includes Myocarditis and Pericarditis Warning for Janssen COVID Vaccine
The revision states that the vaccine can cause thrombosis with thrombocytopenia syndrome, which may be life-threatening.
Tag: pharmaceuticals
All
Latest
All
Latest
ACCP Recommends Removal of OTC Epinephrine for Asthma
The association joins other medical organizations in emphasizing the hazards of over-the-counter availability of inhaled epinephrine products for the treatment of asthma.
All
Latest
Vaccines: Europe OK’s Novavax’s COVID-19 Vaccine Booster
The European Commission expanded the approval of Novavax's COVID-19 vaccine as a booster for adults aged 18 and older.
Experimental ALS Drug NU-9 Superior to Existing Pharmaceuticals
The experimental ALS drug NU-9 is more effective at treating amyotrophic lateral sclerosis than existing FDA-approved drugs for the disease, according to research from Northwestern University scientists published in Scientific Reports.
Read More
Severe COVID Patients Treated with Imatinib Had Lower Mortality Rates
Patients with severe COVID-19 who were treated with imatinib had lower mortality rates at 90-day follow-up, according to research presented at ATS 2022.
Read More
Avacopan Reduced Respiratory/ENT Symptoms in ANCA Vasculitis
Among in ANCA-associated vasculitis patients, Avacopan was better than Prednisone in reducing respiratory and ear, nose and throat (ENT) involvement, while reducing glucocorticoid use.
Read More
Acthar Gel Improved Symptoms in African Americans with Sarcoidosis
A majority of African American patients with symptomatic sarcoidosis treated with Acthar Gel saw clinical improvement in a number of health factors, including lung function and quality of life, according to data presented at ATS 2022.
Read More
Tezepelumab Improved Severe Asthma in Half of Patients
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
Read More
FDA Expands Authorization of Pfizer COVID Booster to Kids 5-through-11
Children age 5-through-11 are now authorized to receive the Pfizer COVID booster at least five months after completion of their primary two-dose series of the Pfizer vaccine.
Read More
Albuterol + Budesonide Cut Risk of Asthma Exacerbation by 27%
Two combinations of albuterol and budesonide used as a rescue medication demonstrated a statistically significant reduction in the risk of a severe exacerbation in patients with moderate to severe asthma.
Read More
FDA Approves Olumiant for Hospitalized COVID Patients
The FDA approved Olumiant (baricitinib) for hospitalized adults with COVID-19 requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO.
Read More
Research to Focus on Use of Azithromycin for Wheeze, Asthma in Preschoolers
Researchers at the University of Arizona Health Sciences are using a $6.7 million National Institutes of Health grant to study azithromycin therapy in preschoolers who are diagnosed with severe wheezing episodes at hospital emergency departments.
Read More
Asthma Drug Montelukast Can Block Crucial SARS-CoV-2 Protein
Asthma and allergy drug montelukast (Singulair) can bind to and block a protein produced by the virus SARS-CoV-2 and reduce viral replication.
Read More
Pfizer Submits Pediatric COVID Booster for Authorization
Pfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.
Read More
FDA Expands Approval of Remdesivir for Pediatric Patients
The US FDA expanded the approval of remdesivir (Veklury, Gilead Sciences) to include pediatric patients 28 days of age and older weighing at least 3 kg with positive results of direct SARS-CoV-2 viral testing.
Read More